Vaccine for brain tumors in children and young adults
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 39 years old.
- You must have one of these tumor types: recurrent medulloblastoma, newly diagnosed high-grade glioma, or newly diagnosed DIPG.
- You must have already received standard treatment (like radiation) for your tumor, unless you are under 4 years old with medulloblastoma.
- Your tumor must be visible on an MRI scan.
- You need to have adequate organ function (liver, kidney, bone marrow) and be free from serious infections or major heart, lung, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial is testing a virus called DNX-2401, which is injected directly into the tumor, for children and young adults with high-grade brain tumors that have come back or are hard to treat. The goal is to see if this virus can shrink or control the tumor.
This trial tests a new immunotherapy that targets the CMV virus inside your glioblastoma tumor. It is for people who have already completed standard radiation and chemotherapy.
This trial tests an experimental vaccine for glioblastoma, given after the usual radiation and chemotherapy (temozolomide). The goal is to see if the vaccine helps the immune system fight remaining cancer cells.
This trial tests a personalized vaccine made from your own immune cells (a dendritic cell vaccine) that may help your body fight the brain tumor. It is meant for people with DIPG or glioblastoma who have already tried standard treatments but still have tumors.
This trial tests adding a vaccine (UCPVax) with or without the immunotherapy drug pembrolizumab to standard chemotherapy after initial treatment. The goal is to see if these extra treatments can help prevent the brain tumor from coming back.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.